Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
| Autor: | Victoria Bedell, Ricardo Spielberger, Ketevan Gendzekhadze, Vinod Pullarkat, Thai Cao, Raju Pillai, Anh Pham, David S. Snyder, Ahmed Aribi, Stephen J. Forman, Sierra Min Li, Milhan Telatar, Monzr M. Al Malki, Hao Hong, Dennis D. Weisenburger, Samer K. Khaled, David Senitzer, Abbas Padeganeh, Joyce Murata-Collins, Patricia Aoun, Ibrahim Aldoss, Haris Ali, Ryotaro Nakamura, Joycelynne Palmer, Guido Marcucci, Amandeep Salhotra, Michelle Afkhami, Margaret R. O'Donnell, Anthony S. Stein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Allogeneic transplantation Disease Article 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Humans business.industry Myelodysplastic syndromes Neoplasms Second Primary Hematology medicine.disease Prognosis Transplantation ETV6 Leukemia Myeloid Acute International Prognostic Scoring System 030220 oncology & carcinogenesis Myelodysplastic Syndromes Immunology Mutation Stem cell Tumor Suppressor Protein p53 business Complication 030215 immunology |
| Zdroj: | Haematologica |
| ISSN: | 1592-8721 0390-6078 |
| Popis: | Therapy-related myelodysplastic syndrome is a long-term complication of cancer treatment in patients receiving cytotoxic therapy, characterized by high-risk genetics and poor outcomes. Allogeneic hematopoietic cell transplantation is the only potential cure for this disease, but the prognostic impact of pre-transplant genetics and clinical features has not yet been fully characterized. We report here the genetic and clinical characteristics and outcomes of a relatively large cohort of patients with therapy-related myelodysplastic syndrome (n=67) who underwent allogeneic transplantation, comparing these patients to similarly treated patients with de novo disease (n=199). The 5-year overall survival was not different between patients with therapy-related and de novo disease (49.9% versus 53.9%; P=0.61) despite a higher proportion of individuals with an Intermediate-2/High International Prognostic Scoring System classification (59.7% versus 43.7%; P=0.003) and high-risk karyotypes (61.2% versus 30.7%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|